Display options
Cite
Ulukan B, Bihorac A, Sipahioglu T, et al. Role of Tissue Transglutaminase Catalytic and Guanosine Triphosphate-Binding Domains in Renal Cell Carcinoma Progression. ACS Omega. 2020;5(43):28273-28284doi: 10.1021/acsomega.0c04226.
Ulukan, B., Bihorac, A., Sipahioglu, T., Kiraly, R., Fesus, L., & Telci, D. (2020). Role of Tissue Transglutaminase Catalytic and Guanosine Triphosphate-Binding Domains in Renal Cell Carcinoma Progression. ACS omega, 5(43), 28273-28284. https://doi.org/10.1021/acsomega.0c04226
Ulukan, Burge, et al. "Role of Tissue Transglutaminase Catalytic and Guanosine Triphosphate-Binding Domains in Renal Cell Carcinoma Progression." ACS omega vol. 5,43 (2020): 28273-28284. doi: https://doi.org/10.1021/acsomega.0c04226
Ulukan B, Bihorac A, Sipahioglu T, Kiraly R, Fesus L, Telci D. Role of Tissue Transglutaminase Catalytic and Guanosine Triphosphate-Binding Domains in Renal Cell Carcinoma Progression. ACS Omega. 2020 Oct 20;5(43):28273-28284. doi: 10.1021/acsomega.0c04226. eCollection 2020 Nov 03. PMID: 33163811; PMCID: PMC7643270.
Copy Download .nbib Format: NLM
Share it on

ACS Omega. 2020 Oct 20;5(43):28273-28284. doi: 10.1021/acsomega.0c04226. eCollection 2020 Nov 03.

Role of Tissue Transglutaminase Catalytic and Guanosine Triphosphate-Binding Domains in Renal Cell Carcinoma Progression.

ACS omega

Burge Ulukan, Ajna Bihorac, Tarik Sipahioglu, Robert Kiraly, Laszlo Fesus, Dilek Telci

Affiliations

  1. Department of Genetics and Bioengineering, Yeditepe University, Istanbul 34755, Turkey.
  2. Department of Biochemistry and Molecular Biology, University of Debrecen, Debrecen H4010, Hungary.

PMID: 33163811 PMCID: PMC7643270 DOI: 10.1021/acsomega.0c04226

Abstract

Tissue transglutaminase (TG2) is a multifunctional protein that can act as a cross-linking enzyme, GTPase/ATPase, protein kinase, and protein disulfide isomerase. TG2 is involved in cell adhesion, migration, invasion, and growth, as well as epithelial-mesenchymal transition (EMT). Our previous findings indicate that the increased expression of TG2 in renal cell carcinoma (RCC) results in tumor metastasis with a significant decrease in disease- and cancer-specific survival outcome. Given the importance of the prometastatic activity of TG2 in RCC, in the present study, we aim to investigate the relative contribution of TG2's transamidase and guanosine triphosphate (GTP)-binding/GTPase activity in the cell migration, invasion, EMT, and cancer stemness of RCC. For this purpose, the mouse RCC cell line RenCa was transduced with wild-type-TG2 (wt-TG2), GTP-binding deficient-form TG2-R580A, transamidase-deficient form with low GTP-binding affinity TG2-C277S, and transamidase-inactive form TG2-W241A. Our results suggested that predominantly, GTP-binding activity of TG2 is responsible for cell migration and invasion. In addition, CD marker analysis and spheroid assay confirmed that GTP binding/GTPase activity of TG2 is important in the maintenance of mesenchymal character and the cancer stem cell profile. These findings support a prometastatic role for TG2 in RCC that is dependent on the GTP binding/GTPase activity of the enzyme.

© 2020 The Authors. Published by American Chemical Society.

Conflict of interest statement

The authors declare no competing financial interest.

References

  1. Oncotarget. 2015 Aug 21;6(24):20525-39 - PubMed
  2. PLoS One. 2009 Jul 01;4(7):e6123 - PubMed
  3. Mol Cancer. 2010 Jul 08;9:180 - PubMed
  4. Cell Adh Migr. 2018 Mar 4;12(2):138-151 - PubMed
  5. Oncogene. 2013 Mar 7;32(10):1252-65 - PubMed
  6. Amino Acids. 2013 Jan;44(1):63-72 - PubMed
  7. Carcinogenesis. 2008 Oct;29(10):1893-900 - PubMed
  8. Oncogene. 2014 Aug 14;33(33):4193-202 - PubMed
  9. Cancer Res. 2006 Nov 1;66(21):10525-33 - PubMed
  10. Amino Acids. 2017 Mar;49(3):517-528 - PubMed
  11. Int J Mol Sci. 2020 Apr 03;21(7): - PubMed
  12. J Biol Chem. 2016 Apr 22;291(17):9119-32 - PubMed
  13. Cell. 2008 May 16;133(4):704-15 - PubMed
  14. Anticancer Res. 2009 Jun;29(6):1909-19 - PubMed
  15. Amino Acids. 2009 Apr;36(4):659-70 - PubMed
  16. Oncogene. 2005 Mar 17;24(12):2032-41 - PubMed
  17. Clin Cancer Res. 2004 Dec 1;10(23):8068-76 - PubMed
  18. Cell Death Differ. 2006 Sep;13(9):1442-53 - PubMed
  19. Exp Ther Med. 2015 Oct;10(4):1413-1418 - PubMed
  20. Mol Cancer. 2005 Sep 09;4:33 - PubMed
  21. Urol Oncol. 2014 Jan;32(1):25.e13-20 - PubMed
  22. Cell Death Dis. 2016 Mar 31;7:e2163 - PubMed
  23. Cancer Hallm. 2013 Mar;1(1):38-49 - PubMed
  24. Cancer Res. 2006 Sep 1;66(17):8788-95 - PubMed
  25. Cancer Res. 2009 Dec 15;69(24):9192-201 - PubMed
  26. Anticancer Res. 2010 Oct;30(10):4177-86 - PubMed
  27. J Biol Chem. 2009 Jul 3;284(27):17914-25 - PubMed
  28. Cancers (Basel). 2018 Nov 19;10(11): - PubMed
  29. PLoS One. 2011;6(6):e20701 - PubMed
  30. PLoS One. 2010 Oct 12;5(10):e13390 - PubMed
  31. Oncotarget. 2017 Mar 21;8(12):20025-20041 - PubMed
  32. Breast Cancer Res. 2012 Jan 06;14(1):R4 - PubMed
  33. Mol Cancer. 2011 Jul 21;10:87 - PubMed
  34. FEBS J. 2011 Dec;278(24):4704-16 - PubMed
  35. Oncogene. 2007 Apr 12;26(17):2459-70 - PubMed
  36. Neoplasia. 2013 Jun;15(6):609-19 - PubMed
  37. Cancer Res. 2008 Jul 15;68(14):5849-58 - PubMed
  38. Cancer Treat Rev. 2008 May;34(3):193-205 - PubMed
  39. Breast Cancer Res. 2013 Feb 25;15(1):202 - PubMed
  40. World J Urol. 2014 Jun;32(3):631-42 - PubMed
  41. Mol Carcinog. 2015 Oct;54(10):947-58 - PubMed
  42. PLoS One. 2009 Aug 06;4(8):e6529 - PubMed
  43. Pharmacol Ther. 2007 Aug;115(2):232-45 - PubMed
  44. J Biol Chem. 2010 Dec 17;285(51):40212-29 - PubMed
  45. J Urol. 1998 Nov;160(5):1883-8 - PubMed
  46. Mol Cancer Ther. 2005 Sep;4(9):1293-302 - PubMed
  47. Drug Resist Updat. 2007 Aug-Oct;10(4-5):144-51 - PubMed
  48. Am J Cancer Res. 2015 Feb 15;5(3):1169-79 - PubMed
  49. Eur J Cancer. 2013 May;49(7):1692-705 - PubMed
  50. Physiol Rev. 2014 Apr;94(2):383-417 - PubMed
  51. Cell. 2009 Nov 25;139(5):871-90 - PubMed
  52. Amino Acids. 2013 Jan;44(1):119-27 - PubMed
  53. FASEB J. 2013 Sep;27(9):3487-95 - PubMed
  54. Cancer Res. 2006 Nov 15;66(22):10936-43 - PubMed
  55. Int Rev Cell Mol Biol. 2012;294:1-97 - PubMed
  56. Oncogene. 2010 Aug 26;29(34):4741-51 - PubMed
  57. J Biol Chem. 2014 Apr 4;289(14):10115-25 - PubMed
  58. Mol Cancer Ther. 2011 Apr;10(4):626-36 - PubMed
  59. Cancer Res. 2006 Dec 1;66(23):11370-80 - PubMed
  60. J Biol Chem. 2003 Oct 24;278(43):42604-14 - PubMed
  61. Cancer Res. 2007 Jan 15;67(2):659-64 - PubMed
  62. Oncotarget. 2016 Sep 27;7(39):64109-64123 - PubMed
  63. N Engl J Med. 2017 Jan 26;376(4):354-366 - PubMed
  64. Oncogene. 2017 May 25;36(21):2981-2990 - PubMed
  65. Oncogene. 2006 May 18;25(21):3049-58 - PubMed
  66. J Biol Chem. 2009 Oct 23;284(43):29547-58 - PubMed
  67. Cancer Res. 2007 Aug 1;67(15):7194-202 - PubMed
  68. Ann Surg Oncol. 2010 Apr;17(4):967-72 - PubMed
  69. Mol Cancer Res. 2015 Jul;13(7):1083-94 - PubMed
  70. Cancer Res. 1999 Sep 1;59(17):4453-7 - PubMed
  71. Stem Cells Int. 2016;2016:8342625 - PubMed
  72. J Biol Chem. 2004 Oct 1;279(40):41461-7 - PubMed
  73. Mol Cancer Res. 2012 Aug;10(8):1109-19 - PubMed
  74. J Pathol Transl Med. 2015 Jan;49(1):37-43 - PubMed
  75. Oncogene. 2012 May 17;31(20):2521-34 - PubMed
  76. J Biol Chem. 2008 Jul 25;283(30):20937-47 - PubMed
  77. Mol Cancer Ther. 2006 Jun;5(6):1493-503 - PubMed
  78. World J Urol. 2015 Oct;33(10):1553-60 - PubMed
  79. J Surg Oncol. 2013 Nov;108(6):414-9 - PubMed
  80. J Cell Mol Med. 2014 Nov;18(11):2235-51 - PubMed
  81. Biochemistry. 2004 Sep 21;43(37):11760-9 - PubMed

Publication Types